Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.
Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.
复制标题
DOI：
10.1186/s12876-017-0618-5
复制
发表时间：
2017-05-10
影响因子：
2.4
通讯作者：
Niu J
中科院分区：
文献类型：
--
作者：
Xu H;Kong W;Liu L;Chi X;Wang X;Wu R;Gao X;Wang H;Qu L;Qi Y;Pan Y;Niu J
Mac-2结合蛋白糖基化异构体（M2 BPGi）是一种新的肝纤维化分期血清学糖生物标志物。在此，我们的目的是评估血清M2 BPGi在中国慢性丙型肝炎感染患者中识别肝纤维化分期的效率。在680名慢性丙型肝炎患者和164名健康对照者中评估了血清M2 BPGi水平，这些患者接受了Fibro Scan®肝纤维化测试。将血清M2 BPG 1值的诊断准确性与其他纤维化标志物的诊断准确性进行比较，所述其他纤维化标志物包括Fibro Scan®、天冬氨酸转氨酶与血小板比率指数（APRI）、基于四个因子的纤维化指数（FIB 4）和γ-谷氨酰转肽酶与血小板比率（GPR）。在慢性丙型肝炎患者中，随着纤维化评分的增加，中位血清M2 BPGi水平增加，如下：0.88（≤F2）、1.70（F2/F3）和5.68（肝硬化）。M2 BPGi浓度也可以区分健康对照组（0.38 ± 0.24）和丙型肝炎患者组（1.57 ± 2.28）。校正潜在混杂因素后，M2 BPGi是与肝硬度测量相关的最显著因素（效应量= 0.275，P < 0.001）。F2和F4患者血清M2 BPGi的最佳临界值分别为0.945和1.355。血清M2 BPGi预测显著纤维化（F ≥ 4）的曲线下面积与APRI相当（0.892 vs.0.873），而其上级优于其他替代标志物，包括FIB 4（0.818）和GPR（0.851）。与其他非侵入性标志物相比，M2 BPGi对诊断丙型肝炎患者肝硬化和肝硬化具有最大的特异性。提示血清M2 BPGi水平可作为慢性肝炎肝纤维化分期的一种简便、可靠的诊断工具。
Mac-2 Binding Protein Glycosylation isomer (M2BPGi) is a novel serological glyco-biomarker for staging liver fibrosis. Here, we aimed to evaluate the efficiency of serum M2BPGi in identifying liver fibrosis stages in Chinese patients with chronic hepatitis C infection. Serum M2BPGi levels were evaluated in 680 patients with chronic hepatitis C and 164 healthy controls who underwent the Fibro Scan® test of liver fibrosis. The diagnostic accuracy of serum M2BPGi values was compared to that of other fibrosis markers, including Fibro Scan®, the aspartate transaminase to platelet ratio index (APRI), the fibrosis index based on four factors (FIB4), and the gamma-glutamyltranspeptidase to platelet ratio (GPR). Among the chronic hepatitis C patients, the median serum M2BPGi level increased with increasing fibrosis score as follows: 0.88 (≤F2), 1.70 (F2/F3), and 5.68 (cirrhosis). M2BPGi concentrations could also distinguish between healthy controls (0.38 ± 0.24) and hepatitis C patients (1.57 ± 2.28). After adjusting for potential confounders, M2BPGi was the most significant factor associated with the liver stiffness measurement (effect size = 0.275, P < 0.001). The optimum cutoff values of serum M2BPGi for patients with F2 and F4 were 0.945 and 1.355, respectively. The area under the curve of serum M2BPGi for prediction of significant fibrosis (F ≥ 4) using was comparable to that of APRI (0.892 vs. 0.873), while it was superior to that of other alternative markers, including FIB4 (0.818) and GPR (0.851). Compared with other non-invasive markers, M2BPGi had the greatest specificity for diagnosing cirrhosis and cirrhosis in hepatitis C patients. Our results suggest that the level of serum M2BPGi would be a simple and reliable diagnostic tool for identifying liver fibrosis stage in Chinese patients with chronic hepatitis.